Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
In Vivo
; 34(5): 3027-3028, 2020.
Article
in English
| MEDLINE | ID: covidwho-740632
ABSTRACT
The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Respiratory Distress Syndrome
/
Coronavirus Infections
/
Raloxifene Hydrochloride
/
Indoles
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
In Vivo
Journal subject:
Neoplasms
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS